"This is an exciting milestone for women in the United Kingdom, and, potentially, in countries around the world, who might prefer this method of contraception and mode of administration." Pfizer Inc.

Self-injection of the contraceptive Sayana Press is both feasible and highly acceptable among women participating in the first such research study conducted in sub-Saharan Africa, according to results ...

The FINANCIAL — Pfizer Inc. announced on September 24 that the company’s injectable contraceptive, Sayana Press (medroxyprogesterone acetate), is now available to women in the United Kingdom (UK) for ...

Access to birth control should be one of the most important aspects of reproductive health care in every country. Fortunately the United Kingdom is taking that notion seriously by making one birth ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc., the Bill & Melinda Gates Foundation, and the Children’s Investment Fund Foundation (CIFF) today announced a multi-year extension of their collaboration to ...

Self-injection of the contraceptive Sayana® Press is both feasible and highly acceptable among women participating in the first such research study conducted in sub-Saharan Africa, according to ...

Pfizer’s Sayana® Press Becomes First Injectable Contraceptive In The United Kingdom Available For Administration By Self-Injection Builds on Current Momentum Towards Broadening Access to This ...

Seattle, November 16, 2016 --Self-injection of the contraceptive Sayana® Press is both feasible and highly acceptable among women participating in the first such research study conducted in ...

Pfizer's (NYSE:PFE) injectable contraceptive, Sayana Press (medroxyprogesterone acetate) is now available to women in the United Kingdom (UK) for administration by self-injection. The approval follows ...